Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Depreciation & Amortization (CF) (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Depreciation & Amortization (CF) for 8 consecutive years, with $5000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 1150.0% to $5000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $178000.0, a 23.61% increase, with the full-year FY2024 number at $193000.0, up 14.2% from a year prior.
  • Depreciation & Amortization (CF) was $5000.0 for Q3 2025 at Whitehawk Therapeutics, down from $16000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $100000.0 in Q4 2024 to a low of $400.0 in Q3 2024.
  • A 5-year average of $37421.1 and a median of $43000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): surged 3600.0% in 2022, then plummeted 99.09% in 2024.
  • Whitehawk Therapeutics' Depreciation & Amortization (CF) stood at $72000.0 in 2021, then crashed by 36.11% to $46000.0 in 2022, then fell by 4.35% to $44000.0 in 2023, then surged by 127.27% to $100000.0 in 2024, then tumbled by 95.0% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Depreciation & Amortization (CF) are $5000.0 (Q3 2025), $16000.0 (Q2 2025), and $57000.0 (Q1 2025).